Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
about
Novel reporter alleles of GSK-3α and GSK-3βAndrographolide reduces cognitive impairment in young and mature AβPPswe/PS-1 miceKinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress.GSK3β, but not GSK3α, inhibits the neuronal differentiation of neural progenitor cells as a downstream target of mammalian target of rapamycin complex1.Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism.WW domain-containing oxidoreductase in neuronal injury and neurological diseases.Effects of paeonol on anti-neuroinflammatory responses in microglial cellsSingle chain variable fragment against aβ expressed in baculovirus inhibits abeta fibril elongation and promotes its disaggregation.Circadian rhythmicity of active GSK3 isoforms modulates molecular clock gene rhythms in the suprachiasmatic nucleus.Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studiesGSK3β isoform-selective regulation of depression, memory and hippocampal cell proliferation.Advances in the pathogenesis of Alzheimer's disease: focusing on tau-mediated neurodegeneration.Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase.Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damageNMDA reduces Tau phosphorylation in rat hippocampal slices by targeting NR2A receptors, GSK3β, and PKC activities.Interactions between GSK3β and amyloid genes explain variance in amyloid burden.Therapeutic strategies for tau mediated neurodegeneration.Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesisUnderstanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease.Targeting the mTOR signaling network for Alzheimer's disease therapy.Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease.Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque.GSK-3β, a pivotal kinase in Alzheimer disease.Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseasesCell-based Models To Investigate Tau Aggregation.Fermenting soybeans with Bacillus licheniformis potentiates their capacity to improve cognitive function and glucose homeostaisis in diabetic rats with experimental Alzheimer's type dementia.Direct High Affinity Interaction between Aβ42 and GSK3α Stimulates Hyperphosphorylation of Tau. A New Molecular Link in Alzheimer's Disease?Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease.A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease.Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.Gene Expression Profiling in Mouse Embryonic Stem Cells Reveals Glycogen Synthase Kinase-3-Dependent Targets of Phosphatidylinositol 3-Kinase and Wnt/β-Catenin Signaling Pathways.A Chemical-Genetic Approach Reveals the Distinct Roles of GSK3α and GSK3β in Regulating Embryonic Stem Cell Fate.A unique type of GSK-3 inhibitor brings new opportunities to the clinic.Glucocorticoid-mediated activation of GSK3β promotes tau phosphorylation and impairs memory in type 2 diabetes.Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice.
P2860
Q28485292-246A4558-AD4D-4EA2-A4B4-62EC05F3A046Q30645309-B7C05A02-7405-4D4C-933F-B4E1E7D5E062Q31122876-7706DCDB-709D-40D2-BAEC-4BBB4226E789Q33588024-22752112-28DD-40BE-B5B4-BCC07746C1EAQ34631209-6E0D7F97-1C17-4A5F-9383-69ECCED06DE8Q35067919-BFD29A33-2F75-4957-80DD-395680A67521Q35585752-322B6C5D-B413-41F9-A474-06CE9A5AB54FQ35616534-A704F804-2A8D-42CB-8CDC-2BD5930CB87BQ36100556-3C6821D4-FE6C-4B3F-B3B6-2FE75481BA14Q36526315-94A07ECF-87F0-42F6-82A1-71F757B251D5Q36649760-A520CBE4-EE23-4501-B5CE-54B9AB89E3C8Q36688393-95FD0119-AE9A-4632-A9CB-5A9A013873DBQ36898190-8327550E-DD22-4B85-8F3C-595EDD0DCEE3Q37302845-0099DF2C-2AAB-45DE-A3FC-28B84E9B5955Q37375713-94E04A91-C060-4191-AB88-EC9E28C9EF82Q37395893-6D1AC633-49EC-4137-B29F-07AFE06520CFQ37550818-64730247-6FD8-47BE-A65B-8B0B102CA45BQ37690524-6B83E553-0D70-4AE3-B6FF-4242548C3538Q38101982-7276F2C0-E2CE-4758-BD02-9C791FE65787Q38118901-430A855A-2FBD-46F8-90A0-D632B3509BB4Q38121524-75A85BDD-BF35-4D8C-BFDA-D4B84257E1A0Q38126701-F06E6898-81F0-481F-8205-957841B52F9FQ38149943-127C1A59-5F0A-4E88-AC8D-458D768CB418Q38170338-EF675E30-D77F-4E43-8F32-11548592AC03Q38218085-FFD16743-90A8-4C81-928E-660FA51C40C0Q38266162-C4CFFD31-8918-487A-B0D2-DAFE4FF7A2ABQ38272835-4191FD49-7D16-4C03-8753-35280A59936EQ38287992-B96ACF06-FF15-4549-A47C-16116F20C206Q38439685-5B610C08-2944-4A00-9AD9-EE746FF4E8A7Q38556871-5A10AE82-151F-41F2-87A9-A0A0427A8988Q38994300-8EB3E271-2CFF-444E-A265-209EAF17B67BQ39135430-C69B1446-BECC-4434-8A51-E8E2DEF99E1DQ41513615-6F015C81-3B12-499D-B496-F401033FF10DQ42005467-D3C457EE-FBEB-4EE3-A839-F1269031B87BQ42183441-6F217120-750B-475E-AEA8-E24B3052A72DQ42266441-774020B7-B8E1-49B4-9AAC-320828DCDE1EQ46193130-70983246-E394-4CFB-9B3F-2AD3CCDAC2EBQ50114697-138A157B-D698-4C69-8F14-BB828E3BEA1CQ50435098-AE605276-10B9-4A47-9FDF-78B6DAE7DEB4Q52151966-237CC0BE-BBC5-4629-86D6-7880DABE4868
P2860
Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Selectively silencing GSK-3 is ...... models of Alzheimer's disease.
@ast
Selectively silencing GSK-3 is ...... models of Alzheimer's disease.
@en
type
label
Selectively silencing GSK-3 is ...... models of Alzheimer's disease.
@ast
Selectively silencing GSK-3 is ...... models of Alzheimer's disease.
@en
prefLabel
Selectively silencing GSK-3 is ...... models of Alzheimer's disease.
@ast
Selectively silencing GSK-3 is ...... models of Alzheimer's disease.
@en
P2093
P2860
P1476
Selectively silencing GSK-3 is ...... models of Alzheimer's disease.
@en
P2093
Awo K Aboagye
Caryn Macdonald
David E Hurtado
Jenna C Carroll
Laura Molina-Porcel
Virginia M-Y Lee
P2860
P304
P356
10.1523/JNEUROSCI.0889-12.2012
P407
P577
2012-05-01T00:00:00Z